TAILORX trial results Monday, September 28

I was just wondering about this today! Thanks for the heads up.

yes me too

Hi:

There is a press release from Genomic Health, Inc. here regarding the conference:

http://files.shareholder.com/downloads/GHDX/731564...

Partial Extract:

"First Read-out from Watershed TAILORx, Largest-Ever Adjuvant Breast Cancer Trial, Accepted as Oral Presentation with "Best Abstract" Designation at Presidential Session
Oncotype DX Becomes First and Only Genomic Breast Cancer Test with Prospective Outcomes Data from Uniformly Treated Patients

REDWOOD CITY, Calif., Sept. 11, 2015 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that results from four Oncotype DX® breast cancer studies, including three large clinical outcomes studies in which the test was used to determine treatment, will be presented at the 2015 European Cancer Congress (ECC 2015) in Vienna, Austria, on September 28.

Included in the ECC 2015 program is the first presentation of clinical outcomes results from the large, prospective Trial Assigning IndividuaLized Options for Treatment (Rx), or TAILORx, which was sponsored by the National Cancer Institute (NCI) in the United States and coordinated by the ECOG-ACRIN Cancer Research Group.

Other presentations include results from a large, multi-center five-year patient outcomes review analysis from Clalit Health Services, Israel, in which the Oncotype DX Recurrence Score® results were systematically incorporated in treatment decision making in early-stage, ER-positive, HER2-negative patients. A separate presentation will highlight prospective survival results from the WSG Phase III plan B trial in Germany.

Presentation details are as follows (all times are European Central Time):

Monday, September 28

• ● Title: "Adjuvant treatment recommendations for ER+ early breast cancer patients by Swiss tumor boards (SAKK 26/10)" (Abstract #1943); B.C. Pestalozzi (Switzerland)
  Poster Session Location: Hall C, Poster Board #132
  Time: 9:15 - 11:15 a.m.
• ● Title: "First prospective outcome data in 930 patients with more than 5-year median follow up in whom treatment decisions in clinical practice have been made incorporating the 21-Gene Recurrence Score" (Abstract #1963); S. Stemmer (Israel)
  Poster Session Location: Hall C, Poster Board #152 Time: 9:15 - 11:15 a.m.
• ● Title: "Clinical impact of risk classification by central/local grade or luminal-like subtype vs. Oncotype DX®: First prospective survival results from the WSG Phase III plan B trial" (Abstract #1937); O. Glutz (Germany) Poster Spotlight Session Location: Hall C, Poster Board #126
  Time: 9:45 - 10:45 a.m.
• ● Title: "Prospective trial of endocrine therapy alone in patients with estrogen-receptor positive, HER2-negative, node- negative breast cancer: Results of the TAILORx low- risk registry" (Abstract #5BA); J. Sparano (U.S.) - Designated a "Best Abstract" by ECC
  Oral Presentation, Presidential Session Location: Hall D1 Time: 5:05 - 5:25 p.m."

BarredOwl

Hi:

I was able to access the text of the first two abstracts only. The others may be embargoed (held until a certain date):

Abstract number: 1943

http://www.europeancancercongress.org/Scientific-P...

Abstract number: 1963

http://www.europeancancercongress.org/Scientific-P...

Please note that abstracts are rather preliminary publications. More data and information will be presented at the conference. Hopefully, fully peer-reviewed publications will follow sooner rather than later. Please discuss any findings with your health care providers.

BarredOwl

Ok got it! There used to be a graph on the oncotype prof site that showed local labs were often a bit more conservative on grade calls than the central (bigger) labs.

Thanks so much! I already read both abstracts. Interesting stuff